The involvement of hypoxia-inducible factor-1α in the susceptibility to γ-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells

International Journal of Cancer

Volumn 120, Issue 2, 2007, Pages 268-277

  Sasabe, Eri ^a   Zhou, Xuan ^a   Li, Dechao ^a,b   Oku, Naohisa ^a   Yamamoto, Tetsuya ^a   Osaki, Tokio ^a  

^a KOCHI UNIVERSITY   (Japan)

^b JIAMUSI UNIVERSITY   (China)

Author keywords

rays; Chemotherapeutic drugs; Heme oxygenase 1; Hypoxia inducible factor 1 ; P glycoprotein

Indexed keywords

CERULOPLASMIN; CISPLATIN; FLUOROURACIL; GLYCOPROTEIN P; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MANGANESE SUPEROXIDE DISMUTASE; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CERULOPLASMIN; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GAMMA RAYS; HEME OXYGENASE-1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MOUTH NEOPLASMS; P-GLYCOPROTEIN; PROMOTER REGIONS (GENETICS); RADIATION TOLERANCE; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; SUPEROXIDE DISMUTASE;

EID: 33845605116     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22294     Document Type: Article

References (48)

1. Brahimi-Horn C, Berra E, Pouyssegur J. Hypoxia: the tumor's gateway to progression along the angiogenic pathway. Trends Cell Biol 2001;11:S32-S36.
2. Goonewardene TI, Sowter HM, Harris AL. Hypoxia-induced pathways in breast cancer. Microsc Res Tech 2002;59:41-8.
3. Czyzyk-Krzeska MF. Molecular aspects of oxygen sensing in physiological adaptation to hypoxia. Respir Physiol 1997;110:99-111.
4. Semenza GL. Tarsetina HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
5. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
6. Brown JM. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 2002;1:453-8.
7. Wouters BG, Weppler SA, Koritzinsky M, Landuyt W, Nuyts S, Theys J, Chiu RK, Lambin P. Hypoxia as a target for combined modality treatments. Eur J Cancer 2002;38:240-57.
8. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
9. Piret JP, Minet E, Cosse JP, Ninane N, Debacq C, Raes M, Michiels C. Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J Biol Chem 2005;280:9336-44.
10. Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C, Miller C, Demonacos C, Stratford IJ, Dive C. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004;24:2875-89.
11. Sasabe E, Tatemoto Y, Li D, Yamamoto T, Osaki T. Mechanism of HIF-1α-dependent suppression of hypoxia-induced apoptosis in squamous cell carcinoma cells. Cancer Sci 2005;96:394-402.
12. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E. Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J Natl Cancer Inst 2001;93:309-14.
13. Bachtiary B, Schindl M, Potter R, Dreier B, Knocke TH, Hainfellner JA, Horvat R, Birner P. Overexpression of hypoxia-inducible factor 1α indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 2003;9:2234-40.
14. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G: Austrian Breast and Colorectal Cancer Study Group. Overexpression of hypoxia-inducible factor 1α is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002;8:1831-7.
15. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, Semenza GL. Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001;61:2911-6.
16. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003;22: 7468-85.
17. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997;40:513-519.
18. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDRI) gene. Cancer Res 2002;62:3387-94.
19. Wartenberg M, Ling FC, Muschen M, Klein F, Acker H, Gassmann M, Pctrat K, Putz V, Hescheler J, Sauer H. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J 2003;17:503-5.
20. Comerford KM, Cummins EP, Taylor CT. c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1α-dependent P-glycoprotein expression in hypoxia. Cancer Res 2004;64:9057-61.
21. Ueta E, Yoneda K, Kimura T, Tatemoto Y, Doi S, Yamamoto T, Osaki T. Mn-SOD antisense upregulates in vivo apoptosis of squamous cell carcinoma cells by anticancer drugs and γ-rays regulating expression of the BCL-2 family proteins, COX-2 and p21. Int J Cancer 2001; 94:545-50.
22. Lee PJ, Jiang BH, Chin BY, Iyer NV, Alam J, Semenza GL, Choi AM. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem 1997; 272:5375-81.
23. Mukhopadhyay CK, Mazumder B, Fox PL. Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem 2000;275:21048-54.
24. Park SY, Chang I, Kim JY, Kang SW, Park SH, Singh K, Lee MS. Resistance of mitochondrial DNA-depleted cells against cell death: role of mitochondrial superoxide dismutase. J Biol Chem 2004;279: 7512-20.
25. Yachie A, Niida Y, Wada T, Igarashi N, Kaneda H, Toma T, Ohta K, Kasahara Y, Koizumi S. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest 1999; 103:129-35.
26. Kim YS, Zhuang H, Kochler RC, Dore S. Distinct protective mechanisms of HO-1 and HO-2 against hydroperoxide-induced cytotoxicity. Free Radic Biol Med 2005;38:85-92.
27. Son E, Jeong J, Lee J, June DY, Cho GJ, Choi WS, Lee MS, Kim SH, Kim IK, Suk K. Sequential induction of heme oxygenase-1 and manganese superoxide dismutase protects cultured astrocytes against nitric oxide. Biochem Pharmacol 2005;70:590-7.
28. Goldstein IM, Kaplan HB, Edelson HS, Weissmann G. Ceruloplasmin. A scavenger of superoxide anion radicals. J Biol Chem 1979; 254:4040-5.
29. Koudi-Paliti A, Smyrniotis V, Frangou M, Papayanopoulou A, Englezou M, Deligeorgi H. Immunohistochemical study of ceruloplasmin, lactoferrin and secretory component expression in neoplastic and non-neoplastic thyroid gland diseases. Acta Oncol 2000;39:753-6.
30. Lee CM, Lo HW, Shao RP, Wang SC, Xia W, Gershenson DM, Hung MC. Selective activation of ceruloplasmin promoter in ovarian tumors: potential use for gene therapy. Cancer Res 2004;64:1788-93.
31. Spitz DR, Oberley LW. An assay for superoxide dismutase activity in mammalian tissue homogenates. Anal Biochem 1989;179:8-18.
32. Birner P, Schindl M, Obermair A, Brenenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001;7:1661-8.
33. Hopll G, Wenger RH, Ziegler U, Stallmach T, Gardelle O, Achermann R, Wergin M, Kaser-Holz B, Saunders HM, Williams KJ, Stratford H, Gassmann M, et al. Rescue of hypoxia-inducible factor-1α-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor. Cancer Res 2002;62:2962-70.
34. Carmeliei P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, et al. Role of HIF-1α in hypoxia-mediated apoptosis. cell proliferation and tumour angiogenesis. Nature 1998;394:485-90.
35. Arvold ND, Gulta N, Wang D, Matli M, Deen DF, Warren RS, Haas-Kogan DA. Hypoxia-induced radioresistance is independent of hypoxia-inducible factor-1A in vitro. Int J Radiol Oncol Biol Phys 2005; 62:207-12.
36. Zhang Q, Zhang ZF, Rao JY, Sato JD, Brown J, Messadi DV, Le AD. Treatment with siRNA and antisense oligonucleotides targeted to HIF-1α induced apoptosis in human tongue squamous cell carcinomas. Int J Cancer 2004:111:849-57.
37. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, Katschinski DM, Wenger RH. The hypoxia-inducible factor-1α is a negative factor for tumor therapy. Oncogene 2003;22:3213-20.
38. Aprelikova O, Wood M, Tackett S, Chandramouli GV, Barrett JC. Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection. Cancer Res 2006;66:5641-7.
39. Li L, Lin X, Staver M, Shoemaker A, Semizarov D, Fesik SW, Shen Y. Evaluating hypoxia-inducible factor-1α as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 2005;65:7249-58.
40. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J Biol Chem 2002;277:29936-44.
41. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1α and vascular endothelial growth factor formation. Mol Cancer Ther 2003;2: 235-43.
42. Huang RF, Huang SM, Lin BS, Hung CY, Lu HT. N-acetylcysteine, vitamin C and vitamin E diminish homocysteine thiolactone-induced apoptosis in human promyeloid HL-60 cells. J Nutr 2002;132:2151-6.
43. 2+ in human hepatoma cells. Toxicol In Vitro 2005;19:173-82.
44. Sun Y, Mu Y, Ma S, Gong P, Yan G, Liu J, Shen J, Luo G. The molecular mechanism of protecting cells against oxidative stress by 2-selenium-bridged β-cyclodextrin with glutathione peroxidase activity. Biochim Biophys Acta 2005;1743:199-204.
45. Kietzmann T, Gorlach A. Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression. Semin Cell Dev Biol 2005;16:474-86.
46. Berberat PO, Dambrauskas Z, Gulbinas A, Giese T, Giese N, Kunzli B, Autschbach F, Meuer S, Buchler MW, Friess H. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res 2005;11:3790-8.
47. Wang M, Kirk JS, Venkataruman S, Domann FB, Zhang HJ, Schafer FQ, Flanagan SW, Weydert CJ, Spitz DR, Buettner GR, Oberley LW, Manganese superoxide dismutase suppresses hypoxic induction of hypoxia-inducible factor-1α and vascular endothelial growth factor. Oncogene 2005;24:8154-66.
48. Emerling BM, Platanias LC, Black E, Nebreda AR, Davis RJ, Chandel NS. Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. Mol Cell Biol 2005;25:4853-62.